Skip to main content

The BHP Starter Fellowship – Pip’s story

Pip Nicholson is a clinical lecturer in haematology at BHP founder-member the University of Birmingham, and completed his BHP Starter Fellowship between 2015 and 2016. His research is currently focused on translating tyrosine kinase inhibitors to be used as anti-platelet drugs, and investigating the mechanisms of vaccine-induced thrombocytopaenia with thrombosis. He holds research grants from the British Heart Foundation, Wellcome Trust Translational Discovery Fund, the NIHR and a number of pharmaceutical companies, and is also chair of the HaemSTAR Network. He spoke to BHP about how his experience of the fellowship had led him to this point in his research career.

What attracted you to apply for the fellowship?

The fellowship was announced at a really opportune time for me. I’d just had a discussion with my now supervisor about the idea for the research and we’d been puzzling over how we could fund my salary to allow me to be released from my clinical duties. One of the limitations with other fellowships is that they require such detailed background and large amount of preliminary data. This means that doctors without a research background are effectively excluded from getting their foot on the first rung of the research ladder. While competitive, the BHP fellowship (or ITM fellowship as it was known then), didn’t require such extensive background information and the preliminary data required was a reasonable amount that could be generated by someone without any dedicated research time.

What were the benefits of fellowship?

The fellowship didn’t come with any significant strings attached such as teaching requirements. This meant that I could get on with the job of learning techniques and quickly generating further data to submit for larger, prestigious fellowship applications to support a full PhD.

Were there any challenges during the fellowship?

The main challenge was getting a full research fellowship application written and submitted in time for the various deadlines. To a clinician, a year to learn new skills and develop preliminary data seems like a huge chunk of time (my experience is that clinicians in training are happy if they get an hour to work on our own projects!). But the research environment is very different and long periods of time are required to learn skills, iron out issues with laboratory assays, and gain ethical approvals for the work.

While a year is sufficient time to generate data if you are focussed about things, the deadlines for the full research fellowships didn’t fall nicely near the end of the BHP fellowship and meant I had to put in applications before they were really ready. Towards the end of the fellowship I was still left wondering whether I had any ongoing research funding and this led to quite a lot of anxiety. I was fortunate to be placed in a well-funded lab where the brief shortfall in funding between finishing my BHP fellowship and subsequent funding from a British Heart Foundation Clinical Research Training Fellowship could be picked up.

How much clinical work did you do while undertaking your fellowship?

I very much wanted to keep my ‘hand in’ clinically, and so I did continue doing some clinical work. I was worried that if I didn’t, I wouldn’t be safe to look after patients when I returned on a more regular basis. So, I undertook in one outpatient clinic a week at the Queen Elizabeth Hospital, and I also did daytime on-calls at weekends at about a 1 in 5 frequency. In hindsight I think this probably slightly hindered my progress in the lab and actually my clinical skills probably wouldn’t have suffered significantly if I’d just stopped doing any clinical work for that year of the BHP fellowship.

Did the fellowship help with your clinical practice?

It definitely helped me identify the area of subspecialist clinical practice I wanted to do long term (i.e. thrombosis and haemostasis). It also gave me time to delve more into the clinical literature of this sub specialist area in order to better understand the pathophysiology and existing treatments and where the current limitations are in our knowledge.  I also gained experience in dealing with ethics applications and working with NHS Trust Research and Development departments which have been a useful skill.

Do you feel that the fellowship has helped you with your career development and aspirations?

Without a doubt, if it wasn’t for the BHP fellowship I can’t see how I would have got my foot in the door of the clinical academic world. I’m now a clinical lecturer, chair a national research network and am in the process of applying for intermediate clinical research fellowships to support me in a consultant role and as a senior clinical lecturer. I wouldn’t be in this position without that initial year of funding that the BHP fellowship provided.

What would your advice be to anyone thinking of applying for a BHP fellowship?

Talk to people who have successfully been award the fellowship and have completed it and moved on to higher research degrees and other fellowships. Ask them to look at their successful applications to use as a template. Talk to them about their experience of the fellowship itself. Identify a supportive research environment and speak to various members of that research group (e.g. PhD students and post-doctoral researchers). They are the ones who will be able to tell you what the research training in that group is really like. Don’t just rely on your impression of the supervisor!

BHP launches Seed Fund to invest in innovation

Today (20 June) Birmingham Health Partners officially launches its BHP Seed Fund – a new initiative which will kick-start innovation by providing researchers with up to £100,000 initial investment.

Designed to support our culture of research-embedded healthcare practice while simultaneously addressing common challenges across our member organisations, the Seed Fund will bring together healthcare professionals, academics, students and entrepreneurs, to deliver the initial steps towards implementable solutions. The aim of the fund is to provide early-stage support and proof-of-concept for projects which will have swift impact on patients outcomes and experiences, but can also be further developed or rolled out more widely.

Working with NHS partners, BHP has identified a number of broad themes which are both of key importance to the region, and are also primed for innovation and investment. We will therefore strongly support applications for projects which directly relate to these priority areas for our region:

      • Health data and AI
      • Engineering into health settings
      • Sustainability
      • Health inequalities
      • Health systems and evaluation

BHP Chair, Ed Smith, commented: “Birmingham Health Partners is delighted to offer this opportunity for innovation, funded with seed money to stimulate support and growth for health-based solutions for the West Midlands and beyond. We hope and expect this funding will be exciting for applicants and deliver meaningful contributions.”

Colleagues from all healthcare professional backgrounds working across all BHP’s partner organisations are welcome to apply.

Visit our BHP Seed Fund page for full details

The BHP Starter Fellowship – Shaun’s story

Shaun Thein is a Clinical Research Fellow in Respiratory Medicine at the University of Birmingham, and undertook his BHP Starter Fellowship between November 2020 and November 2021. He’s currently in the second year of an internally-funded PhD, investigating neutrophil dysfunction in COVID-19 patients, as well as undertaking a PGDip in Medical Education. He took some time out to share his experience of participating in a research fellowship during the pandemic.

What attracted you to apply for the fellowship?

I applied for the BHP Starter Fellowship as I had developed a project during my academic clinical fellowship (ACF), but due to the time restrictions and COVID-19 redeployment, I hadn’t accumulated enough pilot data for a strong fellowship application. The BHP fellowship allowed me to collect more data to present a stronger case.

What were the benefits of fellowship?

The main benefits of the fellowship have been the long stretch of dedicated academic time and funding. This has allowed me to recruit patients in a block and have more time to become involved with other projects. I was able to defer finishing the modules I completed as part of my ACF, giving me the option to submit for an MRes if I was unsuccessful in my clinical research training fellowship application.

In addition, I was able to access the support of the College of Medical and Dental Sciences, attending a Scriptoria workshop, statistics courses and weekly seminars.

Were there any challenges during the fellowship?

Due to a further COVID-19 restriction, patient recruitment to the clinical trial my project was linked to was suspended.  As a result, I shifted focus to use my skillset in another project, investigating COVID neutrophil dysfunction.

Unfortunately, I was unable to secure funding after interview, so it was challenging to find a way for me to continue my research and PhD.  I was fortunate that my supervisor was able to internally fund another year of research for me to complete experiments and patient recruitment.

How much clinical work did you do while undertaking your fellowship?

I did extra out-of-hours shifts at a local NHS Trust to supplement my salary, as there was a significant drop when not doing on-call shifts. I continued this throughout my fellowship as it also helped me to feel more confident in maintaining clinical competencies – especially procedural skills.

Did the fellowship help with your clinical practice?

There was significant patient recruitment as part of my project, involving screening, reviewing imaging and consenting patients for research. I have also been involved in helping with clinical trial research as part of my group. Together this has helped me gain confidence in this aspect of clinical work, and I will be more proactive in recruiting patients and advertising clinical trials in the future.  However, being away from day-to-day ward and clinical work will always generate a degree of anxiety when returning.

Do you feel that the fellowship has helped you with your career development and aspirations?

Yes! It has given me the opportunity to complete a PhD, which I would have not been able to do otherwise, and has enabled me to be involved with clinical research trials and work with leaders in these fields. Being released from an on-call rota has also allowed me to pursue other personal developmental opportunities. For instance, I completed a PGCert in Medical Education and I am continuing with the PGDip this year.  I have also been appointed as the Chair of the British Thoracic Society Specialist Trainees Advisory Group.

What would your advice be to anyone thinking of applying for a BHP fellowship?

There is no reason not to!

However, it is important to apply with a project plan, supervisor and supportive group, and to think about alternative plans and contingency plans if funding applications are not successful.

While a year seems much longer than the 3 month blocks in the ACF, it goes by very quickly – the more that you can hit the ground running, the more you will be able to get out of the year.

Healthy Mum, Healthy Baby, Healthy Future: Report Sets out Vision to Deliver Safe, Effective and Accessible Medicines for use in Pregnancy

In a UK-first report launched today, in the House of Commons, leading figures from charity, healthcare, industry, law and academia have outlined a collaborative vision for UK leadership to improve maternal health. The Healthy Mum, Healthy Baby, Healthy Future: The Case for UK Leadership in the Development of Safe, Effective and Accessible Medicines for Use in Pregnancy report proposes a clear roadmap to improve the lives of millions of people, not just for women while they are pregnant, but for future generations.

Download the report Healthy Mum, Healthy Baby, Healthy Future: The Case for UK Leadership in the Development of Safe Medicines for Use in Pregnancy  [PDF, 2mb]

Globally, over 800 women and 12,000 newborns die every day from preventable pregnancy-related complications – that is one woman and 17 babies every 2 minutes. Pregnancy complications affect two lives in one short period of time, yet only two medicines have ever been developed specifically for pregnancy-related conditions, and not a single new medicine for some of the most serious pregnancy-specific conditions has reached women in decades.

Over the past year, a Birmingham Health Partners led Policy Commission – co-chaired by Baroness Manningham-Buller, Co-president of Chatham House and Professor Peter Brocklehurst, University of Birmingham – has heard from key stakeholders on how best to develop safe, effective and accessible medicines for use in pregnancy. Compelling evidence gathered throughout the process has informed eight critical recommendations which, if implemented by government, will successfully prevent needless deaths and find new therapeutics to treat life-threatening conditions affecting mothers and their babies.

Key proposals include strengthening the UK’s research capabilities to address gaps in our biological knowledge; more effective clinical trials support; and harnessing collaborative partnerships between government, universities and the pharmaceutical industry. Importantly, the report advocates for women who have been historically excluded from clinical trials to be a vital part of future research, ensuring they are not left behind and can benefit from modern medical advances. The UK, with its existing track record of pregnancy research, and lifelong NHS health records, is uniquely placed to lead this overdue and vital reform, working alongside global partners to deliver real change.

Commenting on the report, Co-chair, Baroness Manningham-Buller LG, DCB, FMedSci said: “When I was asked to become joint chair of the Commission that has produced this report, I am ashamed to say that I wasn’t aware that there was an acute problem. Despite being at Wellcome for twelve years and Imperial College for six, I had no idea that research into conception and pregnancy was largely neglected and that virtually no drugs had been developed and trialled for pregnant women in the many decades since thalidomide. This leaves women at the mercy both of general diseases, the diseases of pregnancy and drugs which are usually unlicensed. The evidence taken by the Commission in its inquiry convinces us that this urgently needs to change. We suggest how.”

Co-chair, Professor Peter Brocklehurst said: “This report represents a clear and timely platform to improve the care we provide to pregnant and breastfeeding women, by increasing the availability of safe, effective and accessible medicines for their use. The Commission’s role was to provide a blueprint for action and will provide ongoing support in implementing the recommendations set out in this report, as there is an urgent need for action to address this underserved area of medical need. Without it, women and babies will continue to die when they could be saved. They will continue to experience long-term health effects, disability and distress, which might be avoided.

“We strongly urge the scientific, clinical, industry, regulatory, governmental and public sectors to come together to address the recommendations of this Commission. The UK has the opportunity to transform maternal health across the world, improving the lives of mothers, their babies and future generations – let’s not waste it.”

Yasmin Golding, campaigner from the Epilepsy Society, who continues to be affected by the lack of safe and effective medicines said: “As a mixed race woman with epilepsy there are pregnancy risks I cannot avoid, but many I should be able to in the age of modern medicine. This report gives me and other women hope that in the future they will be able to spend more time enjoying pregnancy and less worrying about avoidable risks that threaten them and their baby.”

Sandra Igwe, founder of The Motherhood Group and Co-chair of the National Inquiry into Racial Injustice in Maternity Care welcomed the report by saying: “Giving a voice back to those who are ultimately the most affected is crucial, and an imperative step for us mothers advocating for ourselves. All women, regardless of race, age, and socioeconomic background should be allowed to have safe and effective medicine during their pregnancy. It’s key in building trust, offers more choice, and lowers potential health risks – a springboard in the right direction. These recommendations will specifically further help women like me, who due to the colour of our skin, face health inequalities within maternity care.”

Find out more about Birmingham’s holistic and collaborative approach to maternal health research on our new research spotlight page

Expanded membership signifies ambition for Birmingham Health Partners

The second city’s University-NHS partnership Birmingham Health Partners (BHP) has expanded its membership by welcoming Sandwell and West Birmingham Hospitals NHS Trust (SWBH) on board, joining the University of Birmingham, University Hospitals Birmingham NHS Foundation Trust (UHB), Birmingham Women’s and Children’s Hospitals NHS Foundation Trust (BWC), and West Midlands Academic Health Sciences Network (WMAHSN).

SWBH’s inclusion extends BHP’s research and education capabilities, and builds on many years of successful collaboration between the Trust and BHP members, working on studies and trials in specialties as diverse as cancer immunotherapy, rheumatology and heart disease. The Trust provides acute hospitals and community healthcare services to a population of around 500,000 people across Sandwell, City and Rowley Regis Hospitals, as well as operates the Birmingham and Midland Eye Centre, the regional Sickle Cell and Thalassaemia Centre, and is the regional base for the National Poisons Information Service. It is also currently developing the Midland Metropolitan University Hospital, which will provide acute care services when it opens.

The news also follows publication of a joint report from BHP, Association of the British Pharmaceutical Industry (ABPI) and the Confederation of British Industry (CBI) which showcased the huge potential of the West Midlands’ life science ecosystem and recommended a joined-up approach to regional leadership and collaboration, in order to tackle the specific health burdens of the West Midlands and beyond.

BHP Director Professor David Adams, who is Head of the University of Birmingham’s College of Medical and Dental Sciences, explained: “Our city and region is home to a concentration of multidisciplinary health and life sciences excellence, and has the potential to strengthen the UK’s position as a world leader in the sector. This can only happen if we work inclusively and collaboratively across the Midlands. With a strong track record of research partnership between BHP’s founder-members and SWBH already in place, it is a natural next step to bring the Trust on board as a full member – demonstrating BHP’s regional leadership, commitment to delivering on our recommendations, and dedication to improving the health of our diverse population.”

Professor David Carruthers, Medical Director of SWBH, commented: “We are delighted to be part of BHP and contribute to the development of research in the West Midlands. This will build on the strong track record that SWBH has in delivering research that involves and is relevant to our patients. This partnership will reinforce our commitment to the development of our staff as well as improving the health of our local population through high quality research opportunities.”

BHP is committed to achieving health and economic impact through harnessing the combined strength and expertise of its members.

High-profile appointee to lead Birmingham’s Precision Health Technologies Accelerator

The University of Birmingham has announced the appointment of an experienced academic and industrial pharmaceutical professional to the position of Managing Director of its new Precision Health Technologies Accelerator (PHTA).

Professor Luigi ‘Gino’ Martini joins PHTA Ltd – a wholly-owned subsidiary of the University that will operate the new facility – from the Royal Pharmaceutical Society (RPS) where he has held the role of Chief Scientist for more than three years. With extensive experience in oncology, rare and infectious diseases, and drug development, Gino also brings expertise in policy development and external advocacy to his new appointment in Birmingham.

Gino’s career began with Senior Scientist roles at Scherer Drug Delivery Systems and SmithKline Beecham, before joining GSK – initially as Drug Delivery and Strategic Technologies Manager – rising to Senior Directorships across a 10-year stint.

An experienced academic, Gino was formerly Professor of Pharmaceutical Innovation at King’s College London, as well as undertaking visiting professorships and PhD supervision alongside his industry roles. Prior to his appointment at the RPS, he held senior development and advisory positions with Shire Pharmaceuticals and Roche.

PHTA will be dedicated to the rapid development and translation of innovative therapies and technologies from concept to clinical evaluation. By creating new opportunities for businesses and entrepreneurs to grow and commercialise their ideas, it will enable advanced drugs, diagnostics and devices to reach patients more quickly. This signature facility will be the focal point of the forthcoming Birmingham Health Innovation Campus (BHIC) development, providing up to 6,000sqm of innovation, co-creation and incubation space within BHIC’s Phase 1 building.

Commenting on his appointment, Gino explained: “I see the PHTA as a place where innovators in health and life sciences will have global impact. I am a great believer in catalysing innovation through creating hubs where like-minded individuals can converge, connect and – in its simplest terms – ‘try things out’.

“COVID-19 has shown us that hybrid and multidisciplinary models of working really do work and this is my vision for the PHTA – an ecosystem which benefits from co-location of experts and budding entrepreneurs which also crosses boundaries and taps into skillsets and best practice of other UK regions. It’s an incredibly exciting time to be joining the project and forging these connections.”

Professor Tim Jones, University of Birmingham Provost and Vice-Principal, commented: “Through Birmingham Health Partners we have an established track record in collaborating with industry partners at start-up, scale-up, and global levels. The Precision Health Technologies Accelerator is the next stage in the journey towards cementing our position as a leader in the translation of research and innovation in health and life sciences.

“Gino’s leadership will be pivotal in achieving this aim, drawing on his considerable experience in both the pharmaceutical industry and in research-intensive academic environments. We are delighted to welcome him to Birmingham.”

Set to open in late 2023, BHIC is ambitious 10-acre, £210m development delivered through a long-term collaboration between the University of Birmingham, as landowner, and experienced investor-developers Bruntwood SciTech. It will be the only science park in the region dedicated to health and life sciences, offering premium laboratory, office and incubation facilities to companies specialising in medtech, precision medicine and digital healthcare.

As one of only six national Life Sciences Opportunity Zones, BHIC is attracting significant new inward investment to the region. This includes significant investment of up to £14m from the Greater Birmingham and Solihull Local Enterprise Partnership (GBSLEP) which will support the design and fit-out of the state-of-the-art PHTA facilities.